Provider: Ingenta Connect
Database: Ingenta Connect
Content: application/x-research-info-systems
TY - ABST
AU - Gupta, A.
AU - Asthana, S.
AU - Konwar, R.
AU - Chourasia, M. K.
TI - An Insight Into Potential of Nanoparticles-Assisted Chemotherapy of Cancer Using Gemcitabine and Its Fatty Acid Prodrug: A Comparative Study
JO - Journal of Biomedical Nanotechnology
PY - 2013-05-01T00:00:00///
VL - 9
IS - 5
SP - 915
EP - 925
KW - STEARIC ACID
KW - NUCLEOSIDE ANALOGUE
KW - STEAROYL-GEMCITABINE
KW - POLY-LACTIC-CO-GLYCOLIC ACID
KW - CYTOTOXICITY
N2 - Gemcitabine (dFdC) mediated cancer treatment faces obstacles, due to its high hydrophilicity. A valuable strategy was executed by synthesizing lipophilic fatty acid derivative of dFdC i.e., 4-N-stearoyl gemcitabine (C18dFdC), built-in into polymeric poly-lactic-co-glycolic
acid nanoparticles (PLGA NPs) and compared with that of parent drug. Encapsulation of derivative within NPs was higher (68.24 ± 3.64%) than dFdC and showed comparatively sustained drug release (19.87 ± 1.73% within 12 hours), with a proof of increased biological half life. The
cytotoxicity and flow cytometric analysis displayed enhanced MCF-7 cell inhibition by C18dFdC-NPs with higher uptake compared to dFdC-NPs. Interestingly, like gemcitabine, C18dFdC-NPs did not induce appreciable differences in blood parameters and in vivo tissue
toxicity study demonstrating safe use of derivative at 40 mg/kg dose. In conclusion, the preclinical data obtained in vitro and in vivo demonstrate the C18dFdC-nanocarrier as an advantageous and promising delivery system for cancer treatment along with the potential
to improve the clinical outcome of gemcitabine chemotherapy.
UR - https://www.ingentaconnect.com/content/asp/jbn/2013/00000009/00000005/art00021
M3 - doi:10.1166/jbn.2013.1591
UR - https://doi.org/10.1166/jbn.2013.1591
ER -